Shanghai Junshi Biosciences Co.Ltd(688180) : js113 drug clinical trial application accepted

Shanghai Junshi Biosciences Co.Ltd(688180) ( Shanghai Junshi Biosciences Co.Ltd(688180) ) announced on April 1 that the holding subsidiary Suzhou JunJing biomedicine received the acceptance notice approved and issued by the State Food and drug administration, and the clinical trial application of the fourth generation EGFR inhibitor wj13404 tablets (project code “js113”) was accepted.